I GF-I, A POLYPEPTIDE hormone, is essential for normal development and growth in mammals (1) . IGF-I gene-or IGF-I receptor gene-deleted mice die at or shortly after birth, and those that survive are 70% smaller than wild-type mice; have defects in brain, bone, muscle, and lung; and are infertile (2, 3) . IGF-I may also play a role in tumorigenesis and aging because high concentrations of circulating IGF-I are associated with increased risk of developing breast and prostate cancers (4, 5) , and low IGF-I levels are linked to extended longevity (6, 7) . Although the IGF-I gene is widely expressed in the body (8) , most (ϳ75%) of the circulating IGF-I comes from its gene expression in the liver (9) . Liver expression of the IGF-I gene is mainly controlled at the transcriptional level by GH from the pituitary (8) . Therefore, understanding the mechanism by which GH regulates IGF-I gene expression in the liver is important to understanding how circulating IGF-I concentration is regulated.
The mechanism by which GH regulates IGF-I gene expression in the liver is only beginning to be understood. Studies on signal transducer and activator of transcription (STAT)-5 knockout mice (10, 11) and on rats overexpressing a dominant-negative STAT5b mutant in the liver (12) demonstrate that GH-increased IGF-I gene expression in the rodent liver is primarily mediated by STAT5. The same transcription factor also appears to mediate GH regulation of IGF-I gene expression in the human liver because a missense mutation in the STAT5b gene was associated with reduced serum IGF-I concentration in a man (13) . Through mapping GH-induced deoxyribonuclease I hypersensitive sites, two STAT5 binding sites in intron 2 of the rat IGF-I gene were indicated to mediate STAT5 activation of IGF-I gene expression in the liver (14) . Through mapping STAT5 binding enhancers, two functional STAT5 binding sites were identified approximately 70 kb upstream from the human IGF-I gene (15) , and these two STAT5 binding sites were later found to also mediate GH activation of IGF-I gene expression in the rat liver (16) . The identification of four STAT5 binding sites upstream and downstream from the IGF-I promoter prompted us to conduct this study to determine whether there are additional STAT5 binding sites mediating GH regulation of IGF-I gene expression in the liver. Our results suggest that eight distantly located STAT5 binding sites might mediate GH-induced STAT5 activation of IGF-I gene expression in the mouse liver.
Fourteen mouse IGF-I gene and 5Ј-flanking regions (designated S1-S14, 200 -400 bp each) containing putative STAT5 binding sites were amplified from mouse (C57BL/6) genomic DNA by PCR using 2ϫ PCR master mix (Promega) and sequence-specific primers containing SmaI and KpnI restriction sites at their 5Ј ends ( Table 1 ). The PCR products were digested with restriction enzymes SmaI and KpnI, gel purified using a QIAquick gel extraction kit (QIAGEN Inc., Valencia, CA), and cloned into pGL2TK, a minimal thymidine kinase (TK) promoter-luciferase reporter vector constructed previously (15) . The resulting constructs were named pGL2TK-S1 , -S2, -S3, -S4, -S5, -S6, -S7, -S8, -S9, -S10 , -S11, -S12, -S13, and -S14, respectively. A mouse cytokine inducible SH2-containing protein gene (Cis) promoter region containing four STAT5 binding sites (17, 18) was similarly amplified and cloned to generate the construct pGL2TK-Cis. The IGF-I DNA regions S5, S9, S10, and S11 were ligated and cloned into pGL2TK-S1 at the BamHI and SalI sites to generate the construct pGL2TK-S1S5S9S10S11. An approximately 3.2-kb mouse IGF-I promoter was amplified by PCR from the mouse genomic DNA using gene-specific primers (Table 1 ) and used to replace the TK promoter in pGL2TK-S1 and pGL2TK-S1S5S9S10S11 to generate the constructs pGL2IP1-S1 and pGL2IP1-S1S5S9S10S11, respectively. These promoter-reporter gene constructs were used in the transfection analyses described below.
A 210-bp mouse IGF-I, a 237-bp mouse albumin, and an 81-bp mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA fragments were amplified by standard RT-PCR from mouse liver total RNA using the ImProm-II reverse transcription system (Promega), 2ϫ PCR master mix, and sequence-specific primers (Table 1) . These cDNA fragments were cloned into pGEM-T Easy vector (Promega). The resulting cDNA plasmids served as templates for syntheses of antisense probes for ribonuclease protection assays (RPAs) described below. The inserts in all recombinant plasmids were verified by sequencing.
Animal experiments
Male C57BL/6 mice hypophysectomized by a parapharyngeal approach at age of 4 wk were purchased from Charles River Laboratories (Wilmington, MA). The mice were housed on automatically timed 12-h dark, 12-h light cycles and had free access to standard rodent diet (Harlan Teklad, Madison, WI) and 5% sucrose water. The mice were weighed weekly for the first 2 wk, and those that did not continue to grow were considered completely hypophysectomized. The confirmed hypophysectomized mice at 8 wk old were administered sc with 2 g/g body weight of recombinant bovine GH (National Hormone and Peptide Program, Torrance, CA) or equal amount of PBS. At this or similar supraphysiological dosages, bovine GH has been shown to be effective in restoring normal gene expression or normal growth in GH-deficient mice (11, 19 -21) . The mice were killed 6 h later and the livers collected, immediately used for nuclei isolation, or frozen for RNA extraction. Based on previous studies (22, 23) , expression of IGF-I mRNA in the liver reached maximum by 6 h after a single GH injection.
Breeding pairs of C57BL/6J-Ghrhr lit mice, which contained a mutation in the GHRH receptor (Ghrhr) gene (24, 25) , were purchased from the Jackson Laboratory (Bar Harbor, ME). The mice were maintained as described above and bred to generate GH-deficient homozygous lit/lit offspring. The lit/lit mice were identified based on smaller size, compared with their littermates, and confirmed by genotyping. For genotyping, genomic DNA was extracted from tail clips using a DNeasy tissue kit (QIAGEN) and the Ghrhr DNA region containing the suspected mutation was amplified by PCR using gene-specific primers ( Table 1 ). The amplified DNA was gel purified and sequenced. Lit/lit male mice 4 -5 months old were administered sc with 2 g/g body weight of recombinant bovine GH as described above and were killed for liver collection at 5, 15, and 30 min and 2, 6, and 24 h after the administration. Lit/lit male mice administered with PBS served as controls. The animalrelated procedures were approved by the Virginia Tech Animal Care Committee.
RNA extraction
Total and nuclear RNA were extracted from liver tissue and liver nuclei, respectively. To isolate liver nuclei, an approximately 200-mg fresh liver sample was homogenized in ice-cold PBS at a low speed. The homogenate was centrifuged at 3000 ϫ g for 10 min at 4 C, and the pellet was washed quickly in 10 ml of ice-cold hypotonic buffer composed of 10 mm HEPES (pH 7.9), 1.5 mm MgCl 2 , 10 mm KCl, 0.2 mm phenylmethylsulfonyl fluoride (PMSF), and 0.5 mm dithiothreitol. The pellet was resuspended in 10 ml of the same buffer and homogenized in a glass Dounce homogenizer. The nuclei were collected by centrifugation as described above and frozen for later RNA extraction. All RNA extractions were done using Tri reagent (Molecular Research Center, Cincinnati, OH), according to the manufacturer's protocol. RNA concentration and quality were determined by spectrophotometry and RNA gel electrophoresis, respectively.
RPAs
An RPA was used to analyze liver IGF-I, albumin, and GAPDH mRNAs in the hypophysectomized mice.
32 P-labeled riboprobes for RPA were synthesized from linearized IGF-I, albumin, and GAPDH cDNA plasmids by standard in vitro transcription in the presence of [␣-32 P]CTP (PerkinElmer Life and Analytical Sciences, Wellesley, MA). The probes were purified to remove free [␣-32 P]CTP using G-50 Sephadex columns (Roche Diagnostics Corp., Indianapolis, IN). About 1 ϫ 10 5 dpm of IGF-I or albumin and 1 ϫ 10 5 dpm of GAPDH riboprobes were hybridized with 15 g of total RNA in 20 l of hybridization buffer for about 16 h at 42 C and then digested with ribonucleases A and T 1 at 37 C for 30 min. The digestion was stopped and the undigested RNA fragments precipitated by adding inactivation/precipitation buffer. These steps were performed using a RPAII kit (Ambion, Inc., Austin, TX). The precipitated RNA fragments were resolved in 6% polyacrylamide gels containing 7 m urea. After electrophoresis, the gels were dried, exposed to phosphor screens, and scanned on a Molecular Imager FX System (Bio-Rad, Hercules, CA).
Real-time RT-PCR
Real-time RT-PCR was used to quantify IGF-I and GAPDH mRNAs and IGF-I and albumin pre-mRNAs in the lit/lit mice. Two micrograms of total RNA or nuclear RNA were reverse transcribed to cDNA in a total volume of 20 l using TaqMan reverse transcribing reagents (Applied Biosystems, Foster City, CA), according to the manufacturer's protocol. Real-time PCRs of IGF-I, GAPDH, and albumin cDNAs were performed on 0.2 g of cDNA product in a total volume of 25 l, using Power Sybr Green PCR master mix (Applied Biosystems) on an Applied Biosystems 7300 real-time PCR system. The primers for these PCRs were presented in Table 1 and the conditions for these PCRs were 40 cycles of 95 C for 15 sec and 60 C for 1 min. For RT-PCR of nuclear RNA, a reverse transcription that did not contain the reverse transcriptase was included for each sample to control for genomic DNA contamination. The RT-PCR of each sample was performed in duplicate. The real-time PCR data were analyzed using the cycle threshold (2 Ϫ⌬⌬CT ) method, as recommended by Applied Biosystems.
Chromatin immunoprecipitation assays (ChIP)
A fresh liver sample (ϳ200 mg) was homogenized at a low speed in 6 ml of PBS supplemented with 1% formaldehyde, a protease inhibitor cocktail tablet (Roche), 0.5 mm sodium orthovanadate, 10 mm sodium ␤-glycerophosphate, 50 mm sodium fluoride, and 5 mm sodium pyrophosphate. The homogenate was incubated with gentle rocking at room temperature for 15 min, followed by addition of 125 mm glycine to stop the cross-linking. The homogenate was centrifuged at 3000 ϫ g for 10 min at 4 C, and the pellet was washed once in 10 ml of ice-cold PBS. The pellet was resuspended in 1 ml of lysis buffer, 5 l of protease inhibitors, and 5 l of PMSF, all from a ChIP-IT kit (Active Motif, Carlsbad, CA). The resuspension was incubated on ice for 30 min, followed by homogenization in a glass Dounce homogenizer. The homogenate was centrifuged as described above, and the pelleted nuclei were resuspended in 1 ml of shearing buffer, 5 l of protease inhibitors, and 5 l of PMSF from the ChIP-IT kit. The nuclei were subsequently sheared on ice with 10 pulses of 20 sec sonication using a sonic dismembrator model 100 at setting 3 (Fisher Scientific). Under these conditions, the chromatin was sheared to fragments 200 -500 bp long. Immunoprecipitation of the sheared chromatin was performed as described (26) . Briefly, 100 l of protein G-Dynal beads (Invitrogen, Carlsbad, CA) were conjugated to 3 g of STAT5 antibody (sc-835; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) by overnight incubation at 4 C with gentle rocking. The STAT5 antibody-conjugated beads were collected in 150 l of ChIP immunoprecipitation buffer and 1 l of protease inhibitors from the ChIP-IT kit and were incubated with 50 l of sonicated chromatin at 4 C overnight. The beads were washed and the chromatin was eluted using the reagents from the ChIP-IT kit, essentially following the manufacturer's instructions. The eluted chromatin fragments were reverse cross-linked by overnight incubation at 65 C, and the DNA was extracted using the columns from the ChIP-IT kit, according to the manufacturer's instructions.
The relative abundance of a STAT5 binding site-containing DNA fragment in STAT5 antibody-precipitated chromatin was determined by PCR using 2ϫ PCR master mix (Promega) and sequence-specific primers (Table 1 ). All primers were tested for specificity on sonicated chromatin, i.e. input DNA. The PCR conditions were 30 cycles of 94 C for 30 sec, 60 C for 1 min, and 72 C for 2 min. In each PCR, an albumin promoter region was also amplified. The albumin promoter region was not expected to be bound by STAT5 because it does not contain a putative STAT5 binding site and because it is not regulated by GH (see Results for this). The presence of the albumin promoter DNA in the STAT5 antibodyprecipitated chromatin reflected nonspecific binding of the antibody to chromatin and/or incomplete removal of the unbound chromatin during the ChIP procedure. The PCR products were resolved through standard agarose gels, and the intensities of DNA bands were measured using the National Institutes of Health ImageJ software (Bethesda, MD). The relative abundance of a putative STAT5 binding site-containing chromosomal region in a ChIP DNA sample was obtained by normalizing the intensity of the PCR product for this DNA region to that for the albumin promoter region. This normalization was expected to control for tube-to-tube variation in DNA loading and PCR efficiency in addition to nonspecific antibody-chromatin binding and incomplete removal of nonbound DNA.
EMSAs
Liver nuclei were isolated from lit/lit mice 30 min after GH or PBS injection as described above for ChIP. The nuclei were resuspended in low-salt buffer [20 32 P]ATP (PerkinElmer). Ten micrograms of liver nuclear proteins were incubated with 1 ϫ 10 5 dpm of 32 P-labeled oligonucleotide in a reaction buffer containing 20% glycerol, 20 mm TrisHCl (pH 7.5), 100 mm KCl, 1 mm dithiothreitol, 1 mm EDTA, and 2 g of poly d(IC) for 1 h at 4 C. For the supershift assay, the nuclear proteins were incubated with 2 g of STAT5 antibody (Santa Cruz Biotechnology) or 2 g of rabbit preimmune serum for 1 h at 4 C before being incubated with the labeled oligonucleotide. After the incubation, the DNA-protein mixtures were resolved by electrophoresis through 6% polyacrylamide gels in 0.5ϫ Tris-borate-EDTA buffer. The gels were analyzed by phosphor imaging as described above.
Cell culture, transfection, and luciferase assays
The CHO cells were grown in MEM supplemented with 10% fetal bovine serum, 1 mm glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin under 5% CO 2 at 37 C. The cells at approximately 50% confluency in 24-well plates were transfected with 200 ng of promoterreporter gene plasmid, 200 ng of bovine GH receptor (GHR) expression plasmid (15) , 200 ng of mouse STAT5b expression plasmid (27) , and 1 ng of transfection efficiency control plasmid pRL-CMV (Promega) per well, using FuGENE6 (Roche). Twenty-four hours after the transfection, the medium was replaced with serum-free MEM, and the cells were further cultured for 16 h. The cells were subsequently treated with 500 ng/ml of recombinant bovine GH or PBS for 8 h before being lysed for luciferase assay. Lysis of the cells and luciferase assay were carried out using dual-luciferase reporter assay system (Promega), according to the manufacturer's instructions. The firefly luciferase activity encoded by the promoter-reporter construct was normalized to the renilla luciferase activity encoded by pRL-CMV to control for variation in transfection efficiency.
Statistical analyses
Comparisons between two means were done using t test. Comparisons between multiple means were done using ANOVA followed by the Tukey test. These statistical analyses were performed using the general linear model of SAS (SAS Institute, Inc., Cary, NC). All data are expressed as mean Ϯ sem.
Results

Nineteen of 90 STAT5 binding consensus sequences in approximately 170 kb of mouse IGF-I gene and flanking regions were conserved in the corresponding human sequence
We started this study by identifying consensus sequence of STAT5 binding site, TTCNNNGAA, where N is any nucleotide (28, 29) , which was conserved between the mouse and human chromosomal regions surrounding the IGF-I gene because regulatory elements are often evolutionarily conserved (30, 31) . A search of a 170 kb of mouse genomic sequence (GenBank accession no. AC125082 and AC139754) consisting of approximately 78 kb IGF-I gene (exon 1 to exon 6), approximately 80 kb 5Ј-flanking region and approximately 10 kb 3Ј-flanking region revealed 90 stretches of TTC-NNNGAA. An alignment of the 170-kb mouse DNA sequence with the corresponding human sequence (GenBank accession no. AC010202) using the VISTA program (32) re- 
edu).
c These correspond to the previously identified STAT5 binding sites in the rat and human IGF-I loci (14 -16).
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vealed that 19 of the 90 9-bp STAT5 consensus sequences were conserved in highly similar (Ͼ70% identical) DNA regions (Ͼ100 bp) between the two species (Fig. 1) . Among the 19 conserved STAT5 consensus sequences, five (designated S1a, S1b, S2, S3, and S4) were located in the distal 5Ј-flanking region; two (S5a, S5b) in intron 2; eight (S6, S7, S8, S9, S10a, S10b, S11a, and S11b) in intron 3; one (S12) in intron 5; and three (S13, S14a, and S14b) in exon 6 of the IGF-I gene (Fig. 1 ). S1a and S1b, S5a and S5b, S10a and S10b, S11a and S11b, and S14a and S14b were less than 250 bp apart in the genome (Fig. 1) . S1a, S1b, S5a, and S5b corresponded to the previously identified STAT5 binding sites in the rat and human IGF-I loci (14 -16) .
GH stimulated STAT5 binding to five putative STAT5 binding site-containing chromosomal regions in the mouse liver
We next determined which of the 19 conserved STAT5 consensus sequences, or putative STAT5 binding sites, were bound by STAT5 in the mouse liver in response to GH treatment. We injected the hypophysectomized mice with GH or PBS and used the ChIP assay to measure STAT5 binding to the 14 chromosomal regions (S1-S14) containing one or two of the 19 putative STAT5 binding sites at 6 h after the injection. We also measured STAT5 binding to a Cis gene promoter region that contains four STAT5 binding sites (17, 18) as a positive control. Before the ChIP assays, we confirmed the GH responsiveness of the mice by measuring changes in liver IGF-I mRNA. As shown in Fig. 2A , GH administration increased liver abundance of IGF-I mRNA in the hypophysectomized mice and had no effects on liver expression of albumin or GAPDH mRNA. These results are consistent with previous studies (11, 33) . Figure 2A also shows that some expression of IGF-I mRNA remained in three of the four hypophysectomized mice in the absence of exogenous GH. This continued expression of IGF-I mRNA may be due to incomplete hypophysectomies or suggests regulation of IGF-I mRNA expression by factors in addition to GH.
The ChIP assays showed that the STAT5 antibody precipitated more of the Cis promoter DNA from the GH-treated liver than from the control liver (P Ͻ 0.05), indicating that GH increased binding of STAT5 to the Cis promoter (Fig. 2, B and C). This result is as expected because the Cis promoter contains four putative STAT5 binding sites that have been previously shown to bind to STAT5 (17, 18) . The STAT5 antibody immunoprecipitated significantly more (P Ͻ 0.05) S1, S5, S9, S10, and S11 DNA from the GH-treated liver than from the control liver (Fig. 2, B and C) , whereas it did not enrich the remaining nine IGF-I DNA regions (i.e. S2, S3, S4, S6, S7, S8, S12, S13, and S14) that corresponded to the other 10 putative STAT5 binding sites (Fig. 2, B and C) , suggesting that GH increased STAT5 binding to the IGF-I DNA regions S1, S5, S9, S10, and S11 in the liver. Based on Fig. 2B , there appeared to be more albumin promoter DNA than the IGF-I chromosomal regions S6, S7, and S13 in the immunoprecipitated chromatin from both the GH-treated and the control livers. These differences probably do not indicate STAT5 binding to the albumin promoter because it was not more abundant than most of the other IGF-I DNA regions and the Cis promoter in the same chromatin samples (Fig. 2B) . Lack of a putative STAT5 binding site and not being regulated by GH ( Fig. 2A) also suggest that the albumin promoter is not bound by STAT5. The differences were perhaps caused by more efficient amplification of the albumin promoter than S6, S7, and S13 in the PCRs. Because the GH-increased binding of STAT5 to S1, S5, S9, S10, and S11 was associated with GH-increased IGF-I mRNA, the nine putative STAT5 binding sites in these chromosomal regions may mediate GH-induced STAT5 activation of IGF-I gene expression in the liver.
GH-stimulated binding of STAT5 to S1, S5, S9, S10, and S11 preceded or coincided with GH-stimulated IGF-I gene transcription in the mouse liver
We next conducted a time-course experiment to determine whether GH-stimulated STAT5 binding to the chromosomal regions S1, S5, S9, S10, and S11 preceded GH-stimulated IGF-I gene transcription in the mouse liver. In this experiment, we treated genetically GH-deficient lit/lit mice with GH, collected livers at different times after GH injection, and analyzed STAT5 binding to S1, S5, S9, S10, and S11 as well as other putative STAT5 binding site-containing chromosomal regions using ChIP. We also measured GH-stimulated changes in IGF-I pre-mRNA and mRNA. As shown in Fig.  3A , liver expression of IGF-I pre-mRNA was significantly higher at 30 min after than before GH administration (P Ͻ 0.05) and continued to rise by 2 h after the administration; it started to decline at 6 h after GH administration and was near its basal level by 24 h after the administration. As also shown FIG. 2. GH stimulated STAT5 binding to five putative STAT5 binding site-containing IGF-I chromosomal regions and IGF-I mRNA expression in the mouse liver. A, RPAs of IGF-I, albumin (alb), and GAPDH mRNAs in the livers of four hypophysectomized mice injected with PBS (hypox) and four hypox mice injected with GH (hypox ϩ GH). The arrows point to the ribonuclease-protected IGF-I, albumin, and GAPDH mRNA bands. Y. RNA, Yeast RNA, serving as a negative control in the assay. B, Chromatin immunoprecipitation assays of STAT5 binding to the putative STAT5 binding site-containing chromosomal regions in the mouse liver. Liver chromatin from hypophysectomized mice receiving GH (ϩGH) or PBS (ϪGH) was immunoprecipitated with an anti-STAT5 antibody, and the abundance of 14 putative STAT5 binding site-containing IGF-I DNA regions (S1 to S14) and a Cis promoter region (as a positive control that was known to bind to GH-activated STAT5) as well as an albumin promoter region (as a negative control that was not expected to bind to GH-activated STAT5) in the immunoprecipitated chromatin was quantified by semiquantitative PCR. Shown are representative agarose gel images of PCR analysis of STAT5 antibody-precipitated chromatin. One of the two DNA bands in each lane corresponds to the albumin promoter and the other to S1, S2 . . . S14 or the Cis promoter. C, Relative abundance of S1, S2 . . . S14 or the Cis promoter DNA in STAT5 antibody-precipitated liver chromatin from four ϩGH and four ϪGH hypophysectomized mice. These data were obtained from densitometric analyses of DNA bands like those in B. Relative abundance on the y-axis represents the ratio of the abundance of S1, S2 . . . S14 or the Cis promoter DNA to that of the albumin promoter in the same chromatin sample. * and #, P Ͻ 0.05 and P Ͻ 0.1, respectively, ϩGH vs. ϪGH for the same DNA region. in Fig. 3A , GH administration caused a similar but delayed time-dependent increase in liver IGF-I mRNA: liver IGF-I mRNA expression was significantly higher at 6 h after than before GH administration (P Ͻ 0.05), and it returned to its basal level by 24 h after the administration (Fig. 3A) . The delayed response of IGF-I mRNA to GH obviously reflected the fact that IGF-I mRNA is processed from IGF-I pre-mRNA. These time-dependent GH responses of IGF-I mRNA and pre-mRNA in mice were similar to those in rats (23, 34) . As expected, GH had no effect on liver expression of albumin pre-mRNA or GAPDH mRNA (Fig. 3A) . It should be noted that IGF-I mRNA was not completely absent in the liver of the lit/lit mouse (Fig. 3A) . This observation is consistent with the studies that indicate the presence of some GH and IGF-I in the serum of the lit/lit mouse (35, 36) . The ChIP assays indicated that GH administration increased STAT5 binding to S1, S5, S9, S10, and S11 in a timedependent manner. STAT5 binding to S10 and S11 started to increase 5 min after GH administration and reached the highest level at 2 h; thereafter it declined and returned to its basal level by 24 h after GH administration (Fig. 3, B and C) . GH-increased binding of STAT5 to S1, S5 and S9 appeared to be slightly delayed, compared with that to S10 and S11, with significant increases in STAT5 binding to S9 occurring 15 min after GH administration and significant increases in STAT5 binding to S1 and S5 occurring 30 min after GH administration (Fig. 3, B and C) . Like STAT5 binding to S10 and S11, that to S1, S5, and S9 also peaked at 2 h after GH administration (Fig. 3, B and C) . As expected, GH increased STAT5 binding to the Cis promoter and had no effect on STAT5 binding to the albumin promoter (Fig. 3, B and C) . Interestingly, the GH-increased binding of STAT5 to the Cis promoter peaked at both 15 min and 6 h after GH administration (Fig. 3, B and C) .
A comparison of the time courses of STAT5 binding to S1, S5, S9, S10, and S11 with those of IGF-I pre-mRNA expression indicated that the increases in STAT5 binding to these chromosomal regions preceded or coincided with GH-stimulated increases in IGF-I pre-mRNA expression (Fig. 3) , further suggesting that the STAT5 binding sites in S1, S5, S9, S10, and S11 may mediate GH-induced STAT5 activation of IGF-I gene transcription in the liver.
The putative STAT5 binding sites in S1, S5, S9, S10, and S11 were able to bind to STAT5 in vitro
We next determined whether the 19 putative STAT5 binding sites can directly bind to STAT5 in vitro. We incubated a 15-bp oligonucleotide corresponding to each of the 19 putative STAT5 binding sites with liver nuclear proteins from lit/lit mice treated with GH or PBS. As shown in Fig. 4A, 15 of the 19 oligonucleotides, including S1a, S1b, S2, S3, S5a, S7, FIG. 3 . GH-stimulated binding of STAT5 to chromosomal regions S1, S5, S9, S10, and S11 preceded or coincided with GH-increased IGF-I transcription in the mouse liver. A, Time courses of GH-stimulated expression of IGF-I mRNA and pre-mRNA. Total RNA and nuclear RNA from GH-deficient lit/lit mice (n ϭ 3) at different times after GH administration were analyzed for the abundance of IGF-I mRNA, IGF-I pre-mRNA, GAPDH mRNA (as a total RNA loading control), and albumin pre-mRNA (as a nuclear RNA loading control) by quantitative real-time RT-PCR. Relative mRNA or pre-mRNA abundance at different times after GH administration is presented as changes over that in lit/lit mice not administered with GH (indicated as time 0 in this figure). Note that the x-axis is not drawn to scale. *, P Ͻ 0.05, compared with the zero time value. B, Time courses of GH-stimulated binding of STAT5 to S1, S5, S9, S10, S11, S14 (as a negative control), the Cis promoter (as a positive control), and the albumin promoter (as a DNA loading control) in the livers of lit/lit mice. The ChIP assays were carried out as described for Fig. 2 . Note the time-dependent changes in the abundance of the PCR products from amplifying S1, S5, S9, S10, S11, and Cis but not from S14 or Alb. C, Relative abundance of S1, S5, S9, S10, S11, S14, and Cis promoter DNA in STAT5 antibody-precipitated chromatin from lit/lit mice at different times after GH administration (n ϭ 3 for each time point). These data were obtained by densitometric analyses of DNA bands like those in B. Relative abundance on the y-axis represents the ratio of the abundance of S1, S5, S9, S10, S11, S14, or the Cis promoter DNA at a later time to that at the zero time. Note that the x-axis is not drawn to scale. S8, S9, S10a, S10b, S11a, S11b, S12, S13, and S14a, formed DNA-protein complexes, which appeared to have the same mobility with liver nuclear proteins from the GH-injected mice. The same complexes were not formed between the oligonucleotides and liver nuclear proteins from PBS-treated lit/lit mice. To confirm the presence of STAT5 in and the specificity of these DNA-protein complexes, the oligonucleotide S1a was further analyzed in supershift and competitive gel-shift assays. As shown in Fig. 4B , the DNA-protein complexes formed between the oligonucleotide S1a and the GHtreated liver nuclear proteins were partially supershifted by a STAT5 antibody. The same complexes were completely competed away by a molar excess (10-or 100-fold) of unlabeled oligonucleotide S1a but were barely affected by the same molar excess of an oliogonucleotide that did not contain a STAT5 consensus binding site (Fig. 4C) .
Based on these gel-shift assays, all of the putative STAT5 binding sites in S1, S5, S9, S10, and S11 except the 3Ј end STAT5 binding site in S5 were able to bind to GH-activated liver STAT5 (Fig. 4A) . These data strongly suggest that the GH-stimulated binding of STAT5 to these chromosomal regions in vivo (Figs. 2 and 3) is due to the presence of STAT5 binding sites in them. Based on the gel-shift assays, the putative STAT5 binding sites in S3, S7, S8, S12, S13, and S14 were also able to bind to STAT5 in vitro (Fig. 4A) , but GH did not stimulate STAT5 binding to S3, S7, S8, S12, S13, and S14 in the liver (Figs. 2 and 3) , indicating that transcription factor binding in cells may be chromatin or sequence context dependent.
S1, S5, S9, S10, and S11 were each able to mediate GHinduced STAT5 activation of reporter gene expression
We next determined whether S1, S5, S9, S10, and S11 as well as other putative STAT5 binding site-containing IGF-I DNA regions can mediate GH-induced STAT5 activation of gene expression, using cotransfection assays. In these assays, a luciferase reporter gene construct bearing a minimal TK promoter and one of the 14 STAT5 binding site-containing IGF-I DNA regions (i.e. S1, S2 . . . S14) was cotransfected with a GHR expression plasmid and a STAT5b expression plasmid into CHO cells, and reporter gene response to GH was measured. As shown in Fig. 5 , GH increased reporter gene expression from the constructs containing S1, S5, S9, S10, and S11 by 50 -220%, compared with PBS (P Ͻ 0.05), and GH had no effect on reporter gene expression from the promoter-only plasmid. These data indicate that S1, S5, S9, S10, and S11 can mediate GH-induced STAT5 activation of gene expression.
GH also stimulated reporter gene expression from the FIG. 5. The IGF-I DNA regions S1, S5, S9, S10, and S11 mediated GH-induced STAT5 activation of gene expression. The CHO cells were transfected with a GHR expression plasmid, a STAT5b expression plasmid, a renilla luciferase plasmid (as a transfection efficiency control), and a pGL2TK-based firefly luciferase reporter plasmid that contained S1, S2 . . . S14, or Cis. The CHO cells were treated with PBS or GH for 8 h before dual-luciferase assay. This experiment was repeated four times. Fold activation on the y-axis represents the ratio of reporter gene expression in the presence of GH to that in the presence of PBS. * and #, P Ͻ 0.05 and P Ͻ 0.1, respectively, compared with pGL2TK. FIG. 4 . Eight of the nine putative STAT5 binding sites in S1, S5, S9, S10, and S11 sequences bound to STAT5 in vitro. A, Electrophoretic mobility shift assays of the nineteen putative STAT5 binding sites. 32 P-labeled double-stranded oligonucleotides (15 bp) corresponding to the putative STAT5 binding sites (i.e., S1a, S1b . . . S14b) were incubated with liver nuclear proteins from the lit/lit mice injected with GH (ϩ) or PBS (Ϫ), followed by polyacrylamide gel electrophoresis. Arrow "B" points to DNA-protein complexes formed specifically between some of the oligonucleotides and the GH-treated liver nuclear proteins. B, Supershift assay of the oligonucleotide S1a. In this assay, the 32 P-labeled oligonucleotide S1a was incubated with GH-treated liver nuclear proteins in the presence of anti-STAT5 antibody (anti-STAT5) or rabbit preimmune serum. Arrow "S" indicates a partial supershift of the DNA-protein complex pointed by arrow "B" . Due to extended electrophoresis, the DNA-protein complex in panel A was separated into two bands, which probably reflect phosphorylation of STAT5 at two distinct sites (38) . C, Competitive gel-shift assay of the oligonucleotide S1a. In this assay, the 32 P-labeled oligonucleotide S1a was incubated with GH-treated liver nuclear proteins in the presence of 1ϫ, 10ϫ, or 100ϫ molar excess of unlabeled S1a or unlabeled oligonucleotide H that did not contain a STAT5 binding site. constructs containing S2, S7, and S8, but it had no effect on reporter gene expression from the constructs containing S4 and S6 (Fig. 5 ). These transfection data were consistent with the gel-shift data that the putative STAT5 binding sites in S2, S7, and S8 were able to bind to STAT5, whereas those in S4 and S6 were not (Fig. 4A) . However, GH did not stimulate reporter gene expression from the constructs containing S12, S13, and S14, despite the fact that the putative STAT5 binding sites in these sequences were able to bind to STAT5 in vitro (Fig. 4A) , indicating that STAT5 binding does not always lead to transcriptional activation.
Multiple STAT5 binding sites together mediated greater GH-induced STAT5 activation of reporter gene expression
One possible functional advantage of the presence of multiple STAT5 binding sites in the IGF-I gene is that multiple binding sites can cooperate to mediate greater STAT5 activation of IGF-I gene expression. To test this possibility, GHinduced STAT5 activation of reporter gene expression was compared between a plasmid that contained the S1 region as the enhancer and a plasmid that contained S5, S9, S10, and S11, in addition to S1, as the enhancers. As shown in Fig. 6 , GH-stimulated luciferase activity from the plasmid containing S1, S5, S9, S10, and S11 was 40 -50% greater (P Ͻ 0.05) than that from the plasmid containing S1 in CHO cells, no matter whether the promoter of the plasmid was a TK promoter or an IGF-I promoter. These data suggest that the STAT5 binding sites in S1, S5, S9, S10, and S11 working together may mediate greater STAT5 activation of IGF-I gene expression in vivo.
Discussion
The major results of this study are: 1) GH increased STAT5 binding to four distal intronic regions and one distal 5Ј-flanking region of the IGF-I gene in the mouse liver that together contain nine putative STAT5 binding sites; 2) GHincreased binding of STAT5 to these DNA regions preceded or coincided with GH-increased IGF-I gene transcription in the liver; 3) eight of the nine putative STAT5 binding sites in these DNA regions were found to bind to STAT5 in vitro; 4) each of the five DNA regions was able to mediate GHinduced STAT5 activation of reporter gene expression in cultured cells; and 5) the five DNA regions together mediated a greater GH-induced STAT5 activation of reporter gene expression than did a single DNA region containing two STAT5 binding sites. These results indicate that GH-induced STAT5 activation of IGF-I gene expression in the mouse liver may involve eight STAT5 binding sites located distantly from the IGF-I promoter.
The presence of eight GH-responsive STAT5 binding sites controlling IGF-I gene expression is a stark contrast to the identification of one or two STAT5 binding sites in most STAT5-regulated genes (29, 37). A question therefore arises: why are so many STAT5 binding sites involved in GH regulation of IGF-I gene expression? Our cotransfection analyses have shown that, although each of the five STAT5 binding site-containing IGF-I DNA regions can mediate GH-induced STAT5 activation of gene expression, the magnitude of the activation is relatively small. Our cotransfection analyses also have shown that the five STAT5 binding site-containing regions together mediate greater GH-induced STAT5 activation of reporter gene expression than a single STAT5 binding site-containing region. Therefore, a possible reason for the existence of multiple STAT5 binding sites for GH regulation of IGF-I gene expression is that each of these STAT5 binding sites is transactivationally weak, and a combined action of them is needed to have a significant effect on IGF-I gene transcription. This possibility seems to be supported by our observation that GH-induced maximum binding of STAT5 to the five chromosomal regions containing multiple STAT5 binding sites coincides with GH-induced maximum transcription of the IGF-I gene in the liver. It should be noted that the dosage of bovine GH used in this study was supraphysiological (38) ; the STAT5 binding sites identified in this study therefore may, or may not, correspond to the STAT5 binding sites at physiological GH concentrations. It is possible that not all of the eight STAT5 binding sites identified in this study are activated under physiological concentrations of GH, and it is also possible that the STAT5 binding sites identified in this study may be selectively activated in the liver, depending on the physiological condition of the animal.
Two of the STAT5 binding sites identified in this study lie more than 70 kb 5Ј from the transcription start site of the IGF-I gene, and five of the remaining six are located at least 26 kb downstream from the transcription start site. The distal locations of these GH-responsive STAT5 binding sites seem to explain previous failure to identify GH-responsive elements in the IGF-I promoter or proximal intron in cell culture and transgenic mice (39 -41) and also seem to be in line with the increasing identification of long-range enhancers (42) (43) (44) (45) . But how do these STAT5 binding sites mediate STAT5 action to the IGF-I promoter over seemingly very long distances? Two major models have been proposed for distant enhancerpromoter interaction (42, 43) . One is the looping model, in which the long intervening DNA loops out to allow direct contact between the transcription factor bound at the distant FIG. 6. S1, S5, S9, S10, and S11 together mediated greater STAT5 activation of gene expression than did S1. The plasmids pGL2TK-S1 contained the TK promoter as the promoter and S1 as the enhancer. The plasmid pGL2IP1-S1 contained a 3.2-kb mouse IGF-I promoter and S1. The plasmids pGL2TK-S1S5S9S10S11 and pGL2IP1-S1S5S9S10S11 contained S5, S9, S10, and S11 in addition to S1 as the enhancers. The cotransfection analyses to compare GH-activated luciferase expression from these plasmids were conducted essentially as described for Fig. 5 . *, P Ͻ 0.05, compared with pGL2TK-S1 or pGL2IP1-S1.
enhancer and the general transcription machinery or sequence-specific transcription factors bound at the promoter; the other model is the tracking model, and based on this model, the transcription factor and perhaps other associated proteins bound at the distant enhancer track along the intervening DNA to the promoter. Increasing evidence favors the looping model (43) . For example, it was recently reported that an interchromosomal enhancer regulates expression of olfactory receptor genes through direct physical contact with the olfactory receptor gene promoters (45) . We speculate that the eight distal STAT5 binding sites in the IGF-I gene affect its transcription also through physical association with the IGF-I promoter. Such a physical association would not only allow direct STAT5 interaction with the general transcription machinery and/or sequence-specific transcription factors bound at the promoter but also bring all the distal STAT5 binding sites together for potential STAT5-STAT5 interaction, which has been shown to benefit STAT5 binding and STAT5 transactivation (17, 46, 47) .
Our in vitro and in vivo DNA-protein binding analyses indicate that several STAT5 binding sites (S2, S3, S7, S8, S12, S13, and S14) can bind to STAT5 in vitro, but their corresponding chromosomal regions do not bind to GH-activated STAT5 in the liver. Whereas these data underscore the importance of validating the physiological relevance of in vitro observations, they also make one wonder why the STAT5 binding sites in S1, S5, S9, S10, and S11 can bind to STAT5 both in vitro and in vivo. As pointed out earlier, S1, S5, S10, and S11 each contain a pair of STAT5 binding sites. Although S9 contains only one conserved STAT5 binding site, there is a nonconserved STAT5 consensus site 240 bp upstream from the conserved STAT5 binding site. Two adjacent STAT5 binding sites located on the same side of the DNA helix can stabilize each other's binding to STAT5 through formation of STAT5 tetramers (46) . It is therefore tempting to speculate that the paired STAT5 binding sites in S1, S5, S9, S10, and S11 might allow for the formation of STAT5 tetramers or some type of STAT5-STAT5 interaction, thereby strengthening their binding to STAT5 in vivo. Alternatively, S1, S5, S9, S10, and S11 might contain binding sites for other transcription factors, and the binding of these other transcription factors either makes the neighboring chromatin more accessible to STAT5 or makes STAT5 binding to the chromatin more stable.
Have all the STAT5 binding sites involved in GH stimulation of IGF-I gene expression been identified? In this study, the identification of the eight STAT5 binding sites from a list of evolutionarily conserved STAT5 consensus sequences was initially based on the observation that the chromosomal regions containing them were bound by STAT5 in the liver at 6 h after GH treatment. It has been shown that STAT5 activation and nuclear translocation can occur within as short as 15 min of GH administration (38) , and our time course experiment in this study also indicated that maximal STAT5 binding to chromatin in the lit/lit mouse liver may occur long before 6 h after GH injection. Therefore, some of the evolutionarily conserved STAT5 consensus sequences that bind to STAT5 only in the early stage of GH action on IGF-I gene expression might have been missed in this study. As just mentioned, the eight STAT5 binding sites were identified from a list of evolutionarily conserved putative STAT5 binding sites on the basis of the widely accepted hypothesis that evolutionarily conserved noncoding sequences have great potential to function as regulatory sequences (30, 31) . However, a recent study comparing transcription factor binding sites between three related yeast species demonstrated that transcription factor binding sites are not necessarily conserved across species (48). Thus, it is possible that some of the unconserved STAT5 consensus sequences that were not tested in this study might be bona fide STAT5 binding sites. Whereas most of the natural STAT5 binding sites conform to the consensus sequence TTCNNNGAA, sequence variants that differ from this consensus sequence by one or two nucleotides have been shown to bind to STAT5, too, at least under in vitro situations (29). The IGF-I locus contains hundreds of such variants of TTCNNNGAA, and some of them might be true STAT5 binding sites.
It is likely that GH regulation of IGF-I gene expression involves transcription factors in addition to STAT5. The human IGF-I promoter contains binding sites for liver-enriched transcription factor hepatocyte nuclear factor (HNF)-3␤ (49, 50) . Mice bearing a truncated GHR have reduced expression of HNF-3␤ protein in the liver (51) . The mouse IGF-I promoter contains three putative HNF-3␤ binding sites, and overexpression of HNF-3␤ significantly enhances reporter gene expression from it in CHO cells (Eleswarapu, S., and H. Jiang, unpublished data). These observations together suggest that GH may induce IGF-I mRNA expression in the liver of the mouse by stimulating HNF-3␤ protein expression. Besides STAT5 and HNF-3␤, many other transcription factors, such as STAT1, STAT3, HNF-1, HNF-4, and HNF-6 are activated or regulated by GH (52, 53) . Therefore, it would not be surprising if some of these transcription factors are found to participate in GH regulation of IGF-I gene expression.
In summary, the results of this study suggest that GHinduced STAT5 activation of IGF-I gene expression in the mouse liver might be mediated by at least eight STAT5 binding sites that are all located distantly from the IGF-I promoter. The identification of multiple distal STAT5 binding sites underscores the complexity of the mechanism that mediates GH regulation of IGF-I gene expression.
